Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Source: seekingalpha
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EPRX
Wall Street analysts forecast EPRX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.290
Low
11.02
Averages
13.02
High
16.03
Current: 6.290
Low
11.02
Averages
13.02
High
16.03
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eupraxia Pharmaceuticals Announces AGM Results
- Board Election Results: At the June 18, 2026, AGM, all seven nominees proposed by Eupraxia Pharmaceuticals were elected with over 90% support, reflecting strong shareholder confidence in management and likely enhancing the stability of the company's governance structure.
- Auditor Reappointment: KPMG LLP was reappointed as the company's auditor at the AGM, with the board authorized to determine the auditor's remuneration, ensuring financial transparency and compliance, which may further boost investor confidence.
- Technology Platform Advantage: Eupraxia's Diffusphere™ technology aims to optimize local drug delivery with potential applications in various therapeutic areas, particularly addressing high unmet medical needs, which could enhance the company's competitive position in the biotechnology sector.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently in a Phase 1b/2 trial targeting eosinophilic esophagitis with a unique local delivery method, and if successful, it could provide innovative treatment options in this field, further expanding the company's product pipeline.
See More
Eupraxia Pharmaceuticals Reports Q1 2026 Financial Results
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $12.7 million for Q1 2026, up from $6.8 million in Q1 2025, primarily due to the doubling of the RESOLVE Part 2 trial size and increased administrative costs, despite a rise in other income, indicating ongoing investment in R&D amid financial pressures.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, down from $80.6 million at the end of Q4 2025, reflecting the company's funding utilization during its R&D expansion.
- Funding Outlook: The company anticipates that its existing cash reserves and proceeds from the anticipated exercise of in-the-money warrants will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future liquidity despite current losses.
- Share Structure: As of March 31, 2026, the company had 61,808,630 common shares and 8,355,638 preferred shares outstanding, indicating stability in its capital structure even while facing financial challenges.
See More
Eupraxia Appoints New Chief Medical Officer
- Executive Transition: Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding the retiring Dr. Mark Kowalski, marking a significant leadership change aimed at advancing the company's gastroenterology pipeline during a critical clinical stage.
- Extensive Experience: Dr. Tambiah brings over 18 years of clinical development and regulatory experience from his tenure at Guys and St Thomas' Hospitals, and his expertise is expected to provide strategic advantages for Eupraxia's EP-104GI project, particularly in treating Eosinophilic Esophagitis.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently undergoing a Phase 1b/2 RESOLVE clinical trial, utilizing a unique local injection method to deliver drugs directly into the esophageal wall, which is anticipated to offer new treatment options for patients.
- Technology Platform Potential: Eupraxia's Diffusphere™ technology aims to optimize localized drug delivery and may expand into oncology and infectious diseases, showcasing its broad application potential in areas with high unmet medical needs.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
Eupraxia Pharmaceuticals Announces AGM Results
- Board Election Results: At the June 18, 2026, AGM, all seven nominees proposed by Eupraxia Pharmaceuticals were elected with over 90% support, reflecting strong shareholder confidence in management and likely enhancing the stability of the company's governance structure.
- Auditor Reappointment: KPMG LLP was reappointed as the company's auditor at the AGM, with the board authorized to determine the auditor's remuneration, ensuring financial transparency and compliance, which may further boost investor confidence.
- Technology Platform Advantage: Eupraxia's Diffusphere™ technology aims to optimize local drug delivery with potential applications in various therapeutic areas, particularly addressing high unmet medical needs, which could enhance the company's competitive position in the biotechnology sector.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently in a Phase 1b/2 trial targeting eosinophilic esophagitis with a unique local delivery method, and if successful, it could provide innovative treatment options in this field, further expanding the company's product pipeline.
See More
Eupraxia Pharmaceuticals Reports Q1 2026 Financial Results
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $12.7 million for Q1 2026, up from $6.8 million in Q1 2025, primarily due to the doubling of the RESOLVE Part 2 trial size and increased administrative costs, despite a rise in other income, indicating ongoing investment in R&D amid financial pressures.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $58.5 million and short-term investments of $80.4 million, down from $80.6 million at the end of Q4 2025, reflecting the company's funding utilization during its R&D expansion.
- Funding Outlook: The company anticipates that its existing cash reserves and proceeds from the anticipated exercise of in-the-money warrants will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future liquidity despite current losses.
- Share Structure: As of March 31, 2026, the company had 61,808,630 common shares and 8,355,638 preferred shares outstanding, indicating stability in its capital structure even while facing financial challenges.
See More
Eupraxia Appoints New Chief Medical Officer
- Executive Transition: Eupraxia Pharmaceuticals has appointed Dr. Jeymi Tambiah as Chief Medical Officer, succeeding the retiring Dr. Mark Kowalski, marking a significant leadership change aimed at advancing the company's gastroenterology pipeline during a critical clinical stage.
- Extensive Experience: Dr. Tambiah brings over 18 years of clinical development and regulatory experience from his tenure at Guys and St Thomas' Hospitals, and his expertise is expected to provide strategic advantages for Eupraxia's EP-104GI project, particularly in treating Eosinophilic Esophagitis.
- Clinical Trial Progress: Eupraxia's EP-104GI is currently undergoing a Phase 1b/2 RESOLVE clinical trial, utilizing a unique local injection method to deliver drugs directly into the esophageal wall, which is anticipated to offer new treatment options for patients.
- Technology Platform Potential: Eupraxia's Diffusphere™ technology aims to optimize localized drug delivery and may expand into oncology and infectious diseases, showcasing its broad application potential in areas with high unmet medical needs.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Data for EP-104GI
- Clinical Trial Progress: Eupraxia Pharmaceuticals reported that in its ongoing Phase 1b/2a RESOLVE trial, EP-104GI demonstrated a reduction of 0.59 and 0.53 in EoEHSS Stage and Grade scores in the highest dose cohort at 36 weeks, reflecting significant improvements of 90% and 88%, indicating positive effects on both inflammatory and structural components of the disease.
- Eosinophil Count Reduction: At week 36, the peak eosinophil count fell by 72% from baseline, marking the largest reduction observed across all dose cohorts, showcasing the potential of EP-104GI in treating eosinophilic esophagitis.
- Good Safety Profile: Among the 31 patients treated, no drug-related serious adverse events were reported for EP-104GI, indicating a favorable tolerability profile that enhances its clinical applicability.
- Long-term Follow-up Data: With over 230 patient-months of follow-up data supporting the safety and efficacy of EP-104GI, this lays a strong foundation for future clinical applications and may enhance Eupraxia's competitive position in the eosinophilic esophagitis treatment market.
See More
Eupraxia Pharmaceuticals Reports Positive Phase 1b/2a Trial Data for Eosinophilic Esophagitis Treatment
- Clinical Trial Results: Eupraxia Pharmaceuticals reported that up to 76% of patients achieved remission in the Phase 1b/2a portion of its RESOLVE trial, with no serious safety concerns, indicating both efficacy and safety of the treatment.
- Remission Rate Analysis: The EP-104GI study revealed that 59% of patients achieved remission at 12 weeks, increasing to 76% at 24 weeks, alongside improvements in swallowing difficulty scores and key disease markers, showcasing the treatment's significant effectiveness.
- New Technology Application: A new cohort utilizing improved catheter delivery demonstrated significantly better outcomes, with the treatment well tolerated across all dose levels and no serious adverse events reported, further validating the safety of the treatment.
- Market Reaction: EPRX became a trending ticker on Stocktwits, reflecting investor interest in its positive clinical data, which may drive the company's future market performance and bolster investor confidence.
See More
Eupraxia Pharmaceuticals Reports Q4 Net Loss of $16.7 Million
- Widening Net Loss: Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, compared to a net loss of $7.5 million in Q4 2024, indicating ongoing pressures in R&D and operations.
- Increased Cash Reserves: As of December 31, 2025, the company had cash reserves of $80.5 million, a significant increase from $33.1 million at the end of Q4 2024, reflecting positive developments in financing efforts.
- Optimistic Funding Outlook: The company anticipates that its existing cash reserves, along with proceeds from the offering and potential future exercise of in-the-money warrants, will be sufficient to fund operations into the second half of 2028, demonstrating confidence in future growth.
- Public Offering Plan: Eupraxia Pharmaceuticals has filed for a proposed public share offering aimed at further enhancing liquidity to support its R&D and market expansion strategies.
See More
